Matinas Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on August 10, 2021. The filing serves to announce the Company's financial results for the quarter ended June 30, 2021, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained within the press release (Exhibit 99.1) and are incorporated by reference, but the text of the press release itself is not included in the source data.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document acts as a notification of the results rather than a detailed comparative analysis.
Guidance, Outlook, and Risks
The filing does not provide specific guidance, outlook, management commentary, or risk factors within the main body text. It notes that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability of the referenced press release content.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 10, 2021) for specific Q2 2021 financial figures.
- Verify the Company's cash position and burn rate, as these are critical for a biopharma firm not reporting revenue in this summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of any debt obligations or liquidity events referenced in the full financial statements.